New drug targets rare bile duct cancer in 235-Patient trial

NCT ID NCT04353375

Recruiting now Disease control Sponsor: Hutchmed Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called HMPL-453 in people with advanced intrahepatic cholangiocarcinoma, a type of bile duct cancer, that has a specific genetic change (FGFR2 fusion). The trial aims to see how well the drug shrinks tumors. About 235 adults will take the drug orally in cycles. It is an open-label, single-arm study, meaning everyone gets the drug and no placebo is used.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HMPL-453 tartrate (a targeted cancer drug)
What this could lead to: If successful, this could provide a new treatment option for people with a rare bile duct cancer that has specific genetic changes.
What could go wrong: This is an early-to-mid stage trial with no control group, so results may not confirm benefit. Side effects from the drug are possible and long-term safety is unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED INTRAHEPATIC CHOLANGIOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

intrahepatic cholangiocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED INTRAHEPATIC CHOLANGIOCARCINOMA SOLID TUMOR, ADULT

Contacts and locations

Locations

Chinese PLA General Hospital
RECRUITING

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.